ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.00
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
87.79
-0.43%
Bitcoin
63,090.47
-0.51%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Ab Science (AB) Quote

Ab Science

Ab Science (AB)

AllianceBernstein Holding LP
1.936
0.052
(2.76%)
Closed April 28 11:30AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.936
Bid
1.882
Ask
1.94
Volume
32,531
1.894 Day's Range 1.94
1.55 52 Week Range 6.54
Market Cap
99.078M
Previous Close
1.884
Open
1.894
Last Trade
619
@
1.936
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
134,191
Shares Outstanding
51,071,069
Dividend Yield
-
PE Ratio
-7.28
Earnings Per Share (EPS)
-0.27
Revenue
958k
Net Profit
-13.62M

About Ab Science

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.ab-science.com
Headquarters
Paris, Paris, Fra
Founded
1970
Ab Science is listed in the Pharmaceutical Preparations sector of the Euronext with ticker AB. The last closing price for Ab Science was 1.88 €. Over the last year, Ab Science shares have traded in a share price range of 1.55 € to 6.54 €.

Ab Science currently has 51,071,069 shares outstanding. The market capitalization of Ab Science is 99.08 € million. Ab Science has a price to earnings ratio (PE ratio) of -7.28.

AB Latest News

More News

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY...

April 03 2024
GlobeNewswire Inc.

AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA

AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE SANTÉ CANADA A JUGÉ ADMISSIBLE LA DEMANDE DE...

April 03 2024
GlobeNewswire Inc.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS...

March 13 2024
GlobeNewswire Inc.

AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune

AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune COMMUNIQUÉ DE PRESSE DE...

March 13 2024
GlobeNewswire Inc.

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT Paris, March 7, 2024, 3pm CET AB Science SA (Euronext - FR0010557264 - AB) is providing...

March 07 2024
GlobeNewswire Inc.

AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB Science

AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB Science COMMUNIQUÉ DE PRESSE...

March 07 2024
GlobeNewswire Inc.

AB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre part

AB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre part COMMUNIQUE DE PRESSE...

March 06 2024
GlobeNewswire Inc.

AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30

AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30 COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE LE LUNDI 4 MARS 2024, DE 18H30 A 19H30...

March 01 2024
GlobeNewswire Inc.

AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30

AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30 COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE LE LUNDI 4 MARS 2024, DE 18H30 A 19H30...

February 29 2024
GlobeNewswire Inc.

AB Science annonce que Santé Canada a émis un Avis de Non-Conformité-Retrait (ANC-R) pour le masitinib dans la SLA

AB Science annonce que Santé Canada a émis un Avis de Non-Conformité-Retrait (ANC-R) pour le masitinib dans la SLA COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE SANTÉ CANADA A ÉMIS UN AVIS DE...

February 26 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.054-2.71356783921.992.0251.884647531.95274215DE
4-0.589-23.32673267332.5252.5251.884821722.16490487DE
12-1.324-40.61349693253.263.721.551341912.39710645DE
26-0.274-12.39819004522.214.4651.551279272.85182979DE
52-3.974-67.2419627755.916.541.551468103.23207324DE
156-13.584-87.525773195915.5216.681.551236817.19426205DE
260-2.674-58.00433839484.6121.751.551456078.65143718DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

Discussion

View Full Feed
getmoreshares getmoreshares 7 minutes ago
good job- thanks
CGAC
Monksdream Monksdream 7 minutes ago
OCEA under$2
https://investorshub.advfn.com/uimage/uploads/2024/4/28/dcuutIMG_7819.gif
OCEA
jmoney360 jmoney360 8 minutes ago
Fridays Darkpool
Short Interest 2,409,523 shares - source: FINRA

Short Interest Ratio 0.02 Days to Cover

Off-Exchange Short Volume 20,078,152 shares - source: FINRA (inc. Dark Pool volume)

Off-Exchange Short Volume Ratio 33.90 % - source: FINRA (i
RNVA
VanLoot VanLoot 8 minutes ago
Get a pile of 💩, listen up …you are a pile of 💩
AABB
Catmandoo Catmandoo 8 minutes ago
Was Mersky ever involved in a legitimate business, never, and he bailed on Drnk to Snnc for another scam.. Yes he is still involved with this scam Drnk.
DRNK
bigtalan bigtalan 9 minutes ago
The big thing we need to hear is the court says that the SAGA deal is not legal , then what will happen? Because all the moves where based on having the SAGA shares. GLTA
ENZC
prototype_101 prototype_101 9 minutes ago
Spekkie said, When I asked whether the products were ready and if any issues were outstanding, he clearly said that everything was ready (stability, scaling etc) and the time line was fully intact and there were no changes to that. Tier 1’s are very interested and the number of them significantly in
ASM LWLG
prototype_101 prototype_101 10 minutes ago
Lewrock said, Tuesday will be interesting and several will be listening.

LAST CALL FOR LPO ONLINE MEETING TUESDAY APRIL 30th. Hello from Disneyland Paris, where it's time to escape for a few days holiday. But not before telling you about the upcoming Optica Online Technology meeting o
LWLG
The Great Pumpkin The Great Pumpkin 10 minutes ago
Mark’s take on one of the comments about TFLN:

There is expected to initially be at least a decent amount of market demand for TFLN in the next several years, involving multiple suppliers that are in existence today. It appears that Ciena is already using the material. There are other
LWLG
GetSeriousOK GetSeriousOK 10 minutes ago
75% failure rate. So much better.

What's the failure rate for medical device start-ups with no patents?

Again, congratulations on Sirius XM.
BIEL
Jetmek_03052 Jetmek_03052 11 minutes ago
New Litigation chart (04/26) courtesy of Stokd

https://investorshub.advfn.com/uimage/uploads/2024/4/28/gmtcvstokd_04252024.png
NLST
janice shell janice shell 11 minutes ago
Yeah, that, too...
gitreal gitreal 12 minutes ago
Benny is Enthusiastic about AABB and I want this Investment of his to be the "3rd Time is the Charm"!

You do know that BennyMomoPanther was a compensated promoter on the SRGE scam, right? He had a very long disclosure statement on every post. He wasn't an "enthusiastic investor" as
AABB CRGP
burner67 burner67 12 minutes ago
I don’t think so. What’s the post number and date?
BEGI
Monksdream Monksdream 13 minutes ago
ELEV under $5
https://investorshub.advfn.com/uimage/uploads/2024/4/28/o[endIMG_7818.gif
ELEV
janice shell janice shell 13 minutes ago
The United States isn't investing as much in human capital as other developed countries and its comparative advantage is falling behind as a result. U.S. students' math skills have remained stagnant for decades. The country is falling behind many others which have greatly improved, such as Japan, Po
AJH92 AJH92 14 minutes ago
Share Structure - Updated April 26, 2024

Transfer Agent Verified

No change - no dilution

No changes anticipated as all future acquisitions will use Preferred Z shares

Authorized Shares: 7,000,000,000

Outstanding Shares: 7,000
INCC
Rodney5 Rodney5 15 minutes ago
“ granted motion to dismiss based on 4617”

I think you have it right Donotunderstand. That’s my understanding of what took place at the SCOTUS.
FNMA
Vexari Vexari 15 minutes ago
What is it about life

That make it

So complicated
Teliz2009 Teliz2009 16 minutes ago
Convertible was done before the $4.9M order announced.
WRAP
Monksdream Monksdream 16 minutes ago
Next day settlement begins May 28 per SEC mandate
POET
10nisman 10nisman 17 minutes ago
What was the point of your post, Ian?

Even Roy hinted that he is worried that something is going wrong in revance that he’s not aware of (on the biotech values thread).What are you talking about? Roy said "If I didn’t have first-hand knowledge of how much better Daxxify is, I would b
RVNC
Monksdream Monksdream 18 minutes ago
XAIR under $2
https://investorshub.advfn.com/uimage/uploads/2024/4/28/uxgibIMG_7817.gif
XAIR
ExtremelyBullishZig ExtremelyBullishZig 18 minutes ago
Not really...we expect after 5 years from trial end that we can at least get a drop of data. So you must not have dug deep enough..
AVXL

Your Recent History

EU
AB
Ab Science
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved